The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
about
PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertaintyAtherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazoneAdditive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARsEffect of glitazones on the progression of coronary artery disease in type 2 diabetes patients.Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study.Dynamic, M2-like remodeling phenotypes of CD11c+ adipose tissue macrophages during high-fat diet--induced obesity in mice.Molecular determinants of the cardiometabolic phenotype.Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway.Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse heartsManagement of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.Pioglitazone use and risk of bladder cancer: population based cohort study.Idealized PPARγ-Based Therapies: Lessons from Bench and BedsideThiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanismPPAR agonists as therapeutics for CNS trauma and neurological diseasesRisk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.Diabetic neuropathy and heart failure: role of neuropeptides.Antidiabetic agents and endothelial dysfunction - beyond glucose control.Insulin resistance and vascular dysfunction in chronic kidney disease: mechanisms and therapeutic interventions.Pharmacotherapy for Nonalcoholic Fatty Liver Disease.Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.The effect of pioglitazone on aldosterone and cortisol production in HAC15 human adrenocortical carcinoma cells.Peroxisome Proliferator-Activated Receptor γ Induces the Expression of Tissue Factor Pathway Inhibitor-1 (TFPI-1) in Human Macrophages.Therapeutic Implications of PPARgamma in Cardiovascular Diseases.Ω-3 fatty acids prevent hepatic steatosis, independent of PPAR-α activity, in a murine model of parenteral nutrition-associated liver disease.Targeting leukotriene B4 in inflammation.Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms.Rosiglitazone does not improve vascular function in subjects with chronic kidney disease.Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ.Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner.The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond
P2860
Q27024799-8A440513-5A87-42FF-8700-AD4E5615E9A5Q28512042-B3DEF670-2564-4094-BA35-D4F59BFC921FQ28550672-D237F54E-CC19-4A93-98A5-3B4EE597481DQ33686312-D11925B7-AFB5-4885-9132-37DFFDB10171Q33772312-160DD2BA-82DD-4A5D-85EA-24B26CDFAC95Q33803444-6C38E075-9A29-4FD5-8E37-C9A354F10A8FQ33921392-FA6AB9DE-85B1-4CC1-8A1D-5B950908C9BEQ34290152-C0F51808-3F2B-40F7-883D-A0EA4F5211E2Q34569388-E1B52B57-8717-43AB-82EF-FC0675328314Q34592900-7CC30A14-E720-4837-92E0-7EC6E494423EQ34676639-B3AEFA40-A8B9-4318-9BFA-946F15926129Q36056207-85307B12-0DD0-4FB4-8C5C-CC2E99CD1ADDQ36555556-EB2CE2D2-071C-4C66-A830-D327A1BE84CCQ37400355-EFF0F7A7-0F18-4B90-965A-10BEB65EB8EDQ37460057-8BA2B2A7-6B36-4F62-9AA8-5291A070FA23Q37537808-F7E61D7E-55BB-4C22-9CAC-7315A3CBE289Q37914972-C0398594-3980-4C4F-ADC5-B9527CD62635Q38397635-45059767-9879-408E-90CE-E4D69C344E59Q38587721-19AC983C-1B65-4CF1-81F6-29C47A0D9B51Q38588344-EC02A91C-59CC-43F0-8F20-1E0263439FDAQ38651175-06DFD2DF-04A2-401C-A015-930FFA03B3A9Q38974109-4B42C8E8-7AAB-41A5-B52B-4C2394DEF1E1Q39003245-C7D4C242-A6B8-488B-95E4-E4426443A5C5Q41855435-1BBA2158-24D5-41EA-B4CA-28CB8406B177Q42138385-8DCED706-BEA3-466A-8E2E-1DB38475AD64Q43464822-F5F3847C-6F53-4398-9F6D-1AFB22732FCFQ43826855-1CE647A5-7360-426D-855A-4BD82A5D1A27Q44983950-1E1AAE6B-BBDA-42FA-8127-CB190EB164F3Q45933327-8CE6FC88-856F-4D9D-9D99-A1C482C32A04Q47130302-49ED8656-4209-4D28-9AFC-8E15A1591371Q47388835-29BC1699-5772-49BD-A9BB-2BFD92275291Q58584097-5F8C62C0-23A3-449B-BCB9-C3898797488A
P2860
The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The peroxisome proliferator-ac ...... in vitro and in vivo in mice.
@en
The peroxisome proliferator-ac ...... in vitro and in vivo in mice.
@nl
type
label
The peroxisome proliferator-ac ...... in vitro and in vivo in mice.
@en
The peroxisome proliferator-ac ...... in vitro and in vivo in mice.
@nl
prefLabel
The peroxisome proliferator-ac ...... in vitro and in vivo in mice.
@en
The peroxisome proliferator-ac ...... in vitro and in vivo in mice.
@nl
P2093
P2860
P1476
The peroxisome proliferator-ac ...... r in vitro and in vivo in mice
@en
P2093
Edward S Horton
Gabriela Orasanu
Jorge Plutzky
Osama Hamdy
Pallavi R Devchand
Vedika Nehra
P2860
P304
P356
10.1016/J.JACC.2008.04.055
P407
P577
2008-07-02T00:00:00Z